Fosun Pharma Subsidiary’s Lung Cancer Drug Application Accepted by China Regulator
I'm PortAI, I can summarize articles.
Shanghai Fosun Pharmaceutical's subsidiary, Fosun Wanbang, has had its drug application for Foritinib Succinate Capsules accepted by China's National Medical Products Administration. This drug targets ALK-positive and ROS1-positive non-small cell lung cancer. The acceptance highlights Fosun Pharma's commitment to innovative oncology therapies, potentially enhancing its market position in lung cancer treatment. The current analyst rating for Fosun Pharma's stock (HK:2196) is a Hold with a price target of HK$20.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments